UMP Healthcare Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for UMP Healthcare Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

UMP Healthcare Holdings (HKG:722) Is Paying Out Less In Dividends Than Last Year

Mar 02

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

Dec 01

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

Oct 26

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

Sep 24

UMP Healthcare Holdings (HKG:722) Will Pay A Larger Dividend Than Last Year At HK$0.017

Feb 26

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.03

Nov 16

UMP Healthcare Holdings (HKG:722) Will Pay A Larger Dividend Than Last Year At HK$0.03

Oct 26

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.03

Sep 26

Here's What To Make Of UMP Healthcare Holdings' (HKG:722) Decelerating Rates Of Return

May 13

UMP Healthcare Holdings (HKG:722) Is Paying Out A Larger Dividend Than Last Year

Feb 27

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.028

Nov 27

We Think UMP Healthcare Holdings Limited's (HKG:722) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 19

Investors Can Find Comfort In UMP Healthcare Holdings' (HKG:722) Earnings Quality

Oct 29

UMP Healthcare Holdings' (HKG:722) Dividend Will Be Increased To HK$0.028

Oct 12

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.028

Sep 25

UMP Healthcare Holdings (HKG:722) Might Be Having Difficulty Using Its Capital Effectively

Jul 27

A Look At The Fair Value Of UMP Healthcare Holdings Limited (HKG:722)

Apr 29

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as UMP Healthcare Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:722 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	750	41	92	149	N/A
3/31/2024	744	37	86	166	N/A
12/31/2023	739	34	81	183	N/A
9/30/2023	733	47	81	187	N/A
6/30/2023	728	60	81	190	N/A
3/31/2023	700	64	N/A	N/A	N/A
12/31/2022	673	68	84	168	N/A
9/30/2022	670	70	55	139	N/A
6/30/2022	666	71	26	111	N/A
3/31/2022	671	72	N/A	N/A	N/A
12/31/2021	676	73	123	162	N/A
9/30/2021	647	74	135	167	N/A
6/30/2021	617	74	147	173	N/A
3/31/2021	584	66	93	121	N/A
12/31/2020	551	59	40	69	N/A
9/30/2020	555	59	68	98	N/A
6/30/2020	559	59	96	128	N/A
3/31/2020	587	67	103	132	N/A
12/31/2019	615	75	110	137	N/A
9/30/2019	593	44	71	92	N/A
6/30/2019	570	13	32	47	N/A
3/31/2019	540	8	N/A	N/A	N/A
12/31/2018	509	3	-27	35	N/A
9/30/2018	487	20	-62	31	N/A
6/30/2018	466	38	-98	26	N/A
3/31/2018	475	48	N/A	N/A	N/A
12/31/2017	485	59	N/A	34	N/A
9/30/2017	501	51	N/A	34	N/A
6/30/2017	516	44	N/A	35	N/A
3/31/2017	504	23	N/A	45	N/A
12/31/2016	491	2	N/A	54	N/A
9/30/2016	475	4	N/A	40	N/A
6/30/2016	458	7	N/A	25	N/A
3/31/2016	441	17	N/A	14	N/A
12/31/2015	424	28	N/A	2	N/A
9/30/2015	414	35	N/A	23	N/A
6/30/2015	403	41	N/A	44	N/A
6/30/2014	355	42	N/A	44	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 722's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 722's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 722's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 722's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 722's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 722's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/18 09:51
End of Day Share Price	2024/12/18 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UMP Healthcare Holdings Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kam Wai Kwok	CGS International
Geng Chen	Phillip Securities (HK)

UMP Healthcare Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

UMP Healthcare Holdings Limited Provides Financial Guidance for Fiscal Year 2022

Recent updates

Upcoming dividend of HK$0.02 per share

UMP Healthcare Holdings Limited Approves A Final Dividend for the Year Ended 30 June 2024

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.02

There May Be Some Bright Spots In UMP Healthcare Holdings' (HKG:722) Earnings

Full year 2024 earnings released: EPS: HK$0.051 (vs HK$0.077 in FY 2023)

UMP Healthcare Holdings (HKG:722) Will Pay A Dividend Of HK$0.02

Independent Non-Executive Director recently bought HK$178k worth of stock

Independent Non-Executive Director recently bought HK$152k worth of stock

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.02

Final dividend reduced to HK$0.02

Full year 2024 earnings released: EPS: HK$0.051 (vs HK$0.077 in FY 2023)

UMP Healthcare Holdings Limited, Annual General Meeting, Nov 29, 2024

UMP Healthcare Holdings Limited Proposes Final Cash Dividend for the Year Ended 30 June 2024, Payable on 10 January 2025

UMP Healthcare Holdings Limited to Report Fiscal Year 2024 Results on Sep 25, 2024

Co-CEO & Executive Vice Chairman recently bought HK$83k worth of stock

Executive Chairman recently bought HK$58k worth of stock

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.054 in 1H 2023)

Upcoming dividend of HK$0.013 per share

Executive Chairman recently bought HK$60k worth of stock

UMP Healthcare Holdings (HKG:722) Is Paying Out Less In Dividends Than Last Year

First half dividend reduced to HK$0.013

UMP Healthcare Holdings Limited Announces Interim (Semi-Annual) Ordinary Dividend for the Six Months Ended 31 December 2023, Payable on 19 April 2024

UMP Healthcare Holdings Limited Announces Interim (Semi-Annual) Ordinary Dividend for the Six Months Ended 31 December 2023, Payable on 19 April 2024

UMP Healthcare Holdings Limited to Report First Half, 2024 Results on Feb 28, 2024

Co-CEO & Executive Vice Chairman recently bought HK$115k worth of stock

UMP Healthcare Holdings Limited Announces Change of Company Secretary and Authorised Representatives

Co-CEO & Executive Vice Chairman recently bought HK$81k worth of stock

Co-CEO & Executive Vice Chairman recently bought HK$104k worth of stock

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

Upcoming dividend of HK$0.03 per share at 7.2% yield

UMP Healthcare Holdings Limited Announces Board Changes

Executive Chairman recently bought HK$64k worth of stock

Executive Director recently bought HK$67k worth of stock

Full year 2023 earnings released: EPS: HK$0.077 (vs HK$0.092 in FY 2022)

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

UMP Healthcare Holdings Limited Proposes to Declare Final Dividend for the Year Ended 30 June 2023

Executive Chairman recently bought HK$139k worth of stock

Executive Chairman recently bought HK$70k worth of stock

UMP Healthcare Holdings (HKG:722) Is Due To Pay A Dividend Of HK$0.03

UMP Healthcare Holdings Limited, Annual General Meeting, Nov 24, 2023

Full year 2023 earnings released: EPS: HK$0.077 (vs HK$0.092 in FY 2022)

UMP Healthcare Holdings Limited to Report Fiscal Year 2023 Results on Sep 21, 2023

Independent Non-Executive Director recently bought HK$81k worth of stock

Upcoming dividend of HK$0.017 per share at 5.7% yield

Independent Non-Executive Director recently bought HK$79k worth of stock

UMP Healthcare Holdings (HKG:722) Will Pay A Larger Dividend Than Last Year At HK$0.017

First half 2023 earnings released: EPS: HK$0.054 (vs HK$0.059 in 1H 2022)

UMP Healthcare Holdings Limited to Report First Half, 2023 Results on Feb 23, 2023

Now 22% undervalued

UMP Healthcare Holdings Limited Announces Final Dividend for the Financial Year Ended 30 June 2022, Payable on 27 January 2023

Independent Non-Executive Director recently bought HK$80k worth of stock

UMP Healthcare Holdings Limited Announces Retirement of SUN Yiu Kwong as CEO, with Effect from 1 January 2023

Upcoming dividend of HK$0.03 per share

UMP Healthcare Holdings Limited Approves to Declare A Final Dividend for the Year Ended 30 June 2022

Chairman & CEO recently bought HK$111k worth of stock

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.03

Less than half of directors are independent

Chairman & CEO recently bought HK$101k worth of stock

UMP Healthcare Holdings Limited Proposes Final Dividend for the Year Ended 30 June 2022, Payable on 27 January 2023

UMP Healthcare Holdings (HKG:722) Will Pay A Larger Dividend Than Last Year At HK$0.03

UMP Healthcare Holdings Limited Proposes Final Dividend for the Year Ended 30 June 2022

Executive Director recently bought HK$72k worth of stock

UMP Healthcare Holdings (HKG:722) Is Increasing Its Dividend To HK$0.03

Third quarter 2022 earnings released: EPS: HK$0.017 (vs HK$0.002 in 3Q 2021)

UMP Healthcare Holdings Limited Proposes Final Dividend for the Year Ended 30 June 2022, Payable on 27 January 2023

UMP Healthcare Holdings Limited Provides Financial Guidance for Fiscal Year 2022

UMP Healthcare Holdings Limited to Report Fiscal Year 2022 Results on Sep 23, 2022

Chairman & CEO recently bought HK$158k worth of stock

Independent Non-Executive Director recently bought HK$155k worth of stock

Here's What To Make Of UMP Healthcare Holdings' (HKG:722) Decelerating Rates Of Return

Less than half of directors are independent

Independent Non-Executive Director recently bought HK$80k worth of stock

Upcoming dividend of HK$0.015 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations